NCT03223064View on ClinicalTrials.gov

Accuracy of Lymph Node Imaging in Prostate Cancer: PSMA PET-CT and Nano-MRI

NAUnknownINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 30, 2016

Primary Completion Date

December 31, 2017

Study Completion Date

December 31, 2017

Conditions
Prostate CancerLymph Node Metastases
Interventions
DIAGNOSTIC_TEST

Ferumoxtran-10 enhanced MRI; MRI contrast agent

Patient undergo MRI with an USPIO contrast agent

DIAGNOSTIC_TEST

68Ga PSMA PET-CT

Patient undergo an 68Ga PSMA PET-CT scan

Trial Locations (3)

6500HB

RECRUITING

Radboud University Medical Centre, Nijmegen

Unknown

RECRUITING

Catharina Ziekenhuis Eindhoven, Eindhoven

6532 SZ

RECRUITING

Canisius Wilhelmina Ziekenhuis, Nijmegen

Sponsors

Collaborators (1)

Astellas Pharma Inc
All Listed Sponsors
collaborator

Astellas Pharma Inc

INDUSTRY

collaborator

Canisius-Wilhelmina Hospital

OTHER

collaborator

Catharina Ziekenhuis Eindhoven

OTHER

lead

Radboud University Medical Center

OTHER

NCT03223064 - Accuracy of Lymph Node Imaging in Prostate Cancer: PSMA PET-CT and Nano-MRI | Biotech Hunter | Biotech Hunter